System and method for the production, formulation and use of conditioned media, cultured cells and the factors included therein
AssigneeRinati Skin, LLC
InventorsNathan Newman, Alex Rajangam, Dodanim Talavera-Adame, Harpreet Sidhu
Life of this patent
Estimating the term…
Abstract
A technology regarding the production, formulation and use of conditioned media and the factors included therein is disclosed. The conditioned media may be inoculated with animal cells, plant cells and any combination thereof. The inoculations may occur simultaneous or at different times. Cells retrieved from different areas of the animal and/or the plant may also be cultured together to form conditioned media and associated growth factors.
Claims17
A method of treating lung inflammation and/or coronavirus-induced severe acute respiratory syndrome (SARS-CoV) in a subject comprising:
- (i) culturing fibroblast cells in a first media to produce a first conditioned media;
- (ii) culturing stem cells in successive inoculations in a three-dimensional scaffold in a second media comprising the first conditioned media to produce a second conditioned media, wherein the stem cells are cultured in a dynamic system, thereby producing a composition comprising the second conditioned media;
- and
- (iii) administering to the subject an aerosolized pharmaceutical composition comprising the composition produced in (ii) using an inhaler or a nebulizer, thereby treating the lung inflammation and/or SARS-CoV in the subject.
A method of decreasing lung inflammation, decreasing viral load, and/or promoting tissue regeneration in a subject comprising:
- (i) culturing fibroblast cells in a first media to produce a first conditioned media;
- (ii) culturing stem cells in successive inoculations in a three-dimensional scaffold in a second media comprising the first conditioned media to produce a second conditioned media, wherein the stem cells are cultured in a dynamic system, thereby producing a composition comprising the second conditioned media;
- and
- (iii) administering to the subject an aerosolized pharmaceutical composition comprising the composition produced in (ii),
- wherein the subject has a coronavirus-induced severe acute respiratory syndrome (SARS-CoV), thereby decreasing lung inflammation, decreasing viral load, and or promoting tissue regeneration in the subject.
Dependencies are inferred from the claim text.